---
title: "Research Alert: CFRA Keeps Hold Opinion On Shares Of Globus Medical Inc."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285955961.md"
description: "CFRA maintains a Hold opinion on Globus Medical Inc. (GMED) shares, lowering the target price to $84 from $98. They raised the 2026 EPS estimate to $4.72 and 2027 EPS to $4.98. GMED reported a strong Q1 2026 with a 27% revenue increase to $759.9M and a 64.7% rise in adjusted EPS to $1.12. Growth was driven by the U.S. Spine business, but revenue from the Nevro business declined due to restructuring, indicating potential execution risks ahead."
datetime: "2026-05-11T13:15:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285955961.md)
  - [en](https://longbridge.com/en/news/285955961.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285955961.md)
---

# Research Alert: CFRA Keeps Hold Opinion On Shares Of Globus Medical Inc.

09:15 AM EDT, 05/11/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target to $84 from $98, based on 16.9x our 2027 EPS estimate, below GMED's five-year average forward P/E multiple. We raise our 2026 EPS view to $4.72 from $4.39 and our 2027 EPS forecast to $4.98 from $4.78. GMED reported a strong start to 2026, with first-quarter results significantly exceeding expectations on both revenue and earnings. Total revenue grew 27% Y/Y to $759.9M, while adjusted EPS surged 64.7% Y/Y to a record $1.12. The performance was led by robust, double-digit growth in the core Globus business, particularly in U.S. Spine, which has now grown over 10% for three consecutive quarters. However, the positive results were partially offset by the revenue decline in the recently acquired Nevro business as it undergoes strategic restructuring. Management attributed this to structural changes in the sales and marketing organization, but the CFO acknowledged that the performance would probably get a little bit worse before it gets better, highlighting some execution risk in the near term.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [GMED.US](https://longbridge.com/en/quote/GMED.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [NVRO.US](https://longbridge.com/en/quote/NVRO.US.md)

## Related News & Research

- [VIRGINIA RETIREMENT SYSTEMS ET Al Sells 17,300 Shares of Globus Medical, Inc. $GMED](https://longbridge.com/en/news/286670432.md)
- [Stifel Nicolaus Reaffirms Their Hold Rating on Globus Medical (GMED)](https://longbridge.com/en/news/285872659.md)
- [BUZZ-Dexcom climbs on plans to revamp board panel](https://longbridge.com/en/news/286583878.md)
- [embecta Completes Acquisition of Owen Mumford Holdings Limited](https://longbridge.com/en/news/286571686.md)
- [Herbal Dispatch Completes Company Record 500kg Medical Cannabis Export Shipment to Europe | LUFFF Stock News](https://longbridge.com/en/news/286883156.md)